Biotechnology News

- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 - - Dr....

PETACH TIKVA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by...

FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood...

DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that...

Programs span familial and sporadic ALS, advancing Arbor’s strategic focus on the disease First CNS investigational new drug (IND) filings are anticipated in 2027 Milestone builds on clinical...

— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year —       — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21,...

CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the...

ROCKAWAY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at...

Final pre-MAA package submitted to MHRA on October 20, 2026Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by...

EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026JUNIPER Phase 2 Trial-in-Progress poster...